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cells relies on FBXO11 activity
Sofie Otzen Bagger1, Branden Michael Hopkinson1, Deo Prakash Pandey3,5, Mads Bak1, Andreas Vincent Brydholm1,
Rene Villadsen1, Kristian Helin2,3, Lone Rønnov-Jessen4, Ole William Petersen1,2 and Jiyoung Kim1,2*Abstract
Tumorigenesis is increasingly considered to rely on subclones of cells poised to undergo an epithelial to mesenchymal
transition (EMT) program. We and others have provided evidence, however, that the tumorigenesis of human breast
cancer is not always restricted to typical EMT cells but is also somewhat paradoxically conveyed by subclones
of apparently differentiated, non-EMT cells. Here we characterize such non-EMT-like and EMT-like subclones.
Through a loss-of-function screen we found that a member of the E3 ubiquitin ligase complexes, FBXO11,
specifically fuels tumor formation of a non-EMT-like clone by restraining the p53/p21 pathway. Interestingly, in
the related EMT-like clone, FBXO11 operates through the BCL2 pathway with little or no impact on tumorigenesis. These
data command caution in attempts to assess tumorigenesis prospectively based on EMT profiling, and they emphasize
the importance of next generation subtyping of tumors, that is at the level of clonal composition.
Keywords: Breast cancer, shRNA screening, Collective migration, Non-EMTIn recent years, due to its aggressive behavior, much atten-
tion has been directed towards the basal-like subtype of
breast cancer believed to be caused by cancer stem cell ac-
tivity often considered synonymous to the concept of EMT.
Accordingly, as a consequence of its relatively differenti-
ated, non-EMT-like appearance, the most frequent subtype
of breast cancer, the luminal, has been somewhat under-
studied in this regard. Indeed, the very impact of EMT on
breast cancer has been questioned altogether [1, 2]. With
the purpose of examining cancer stem cell activity among
typical epithelial cells in breast cancer we have previously
focused on comparisons between clonally related
non-EMT-like and EMT-like cells [3]. To our surprise we
found that independently of subtype the non-EMT-like
cells are more tumorigenic and tumor-initiating than the
EMT-like cells [3, 4]. When we cloned cells with a
stem-like profile, we found that they readily generated
luminal-like progeny to indicate the existence of a hierarchy
which could sustain heterogeneity as previously described
for human breast cancer [3]. We also cloned differentiated* Correspondence: jkim@sund.ku.dk
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minal profile which resembles the majority of grade I
luminal breast cancers, i.e. polarized luminal-like cells with-
out signs of basal traits. While the latter clones turned out
to be both highly tumor-initiating and invasive [3], the
question remained open as to how aggressiveness is main-
tained in such clones if not by hijacked stem-cell or estab-
lished EMT-related pathways.
Large-scale loss-of-function screens have been suc-
cessfully applied to identify tumorigenic mechanisms
and in turn have led to discovery of novel targets for
drug intervention [5]. Here, we performed an shRNA
screen in non-EMT-like and EMT-like clones for iden-
tifying differentially depleted shRNAs and found sig-
nificantly depleted shRNAs in a clone-dependent
manner. Based on this, we propose to reappraise path-
ways of tumorigenesis in non-EMT breast cancer sub-
clones and to emphasize clonal heterogeneity as a
supplement to breast cancer subtyping.Characterization of MCF7 breast cancer cell clones
as a model of tumor aggressiveness and FBXO11
as a functional readout
In order to investigate mechanisms alternative to
EMT, which facilitate tumor progression, we used anle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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Fig. 1 Characterization of MCF7 breast cancer cell clones as a model of tumor aggressiveness and FBXO11 as a functional readout. a RT-qPCR
analysis of relative EMT marker expression shows upregulation of epithelial markers CDH1 and OCLN in non-EMT cells and upregulation of
mesenchymal markers SNAI2 and TWIST in EMT-like cells. E-cadherin is encoded by CDH1; occludin by OCLN. Error bars represent SD of quadruplicates.
b Monolayer culture non-EMT-like (left column) and EMT-like (right column) MCF7 clones stained (green) with ZO-1 (upper row), Occludin (middle row),
E-cadherin (lower row), and DAPI (blue, nuclei). Only the non-EMT-like clone exhibits distinct staining at the cell-cell junctions. Bar = 50 μm. c Representative
BLI of NOG mice inoculated with 104 non-EMT-like (left column) or EMT-like (right column) MCF7-pFU-L2G cells (n= 6 inoculations/cell-type). Time
indicates weeks after inoculation. Non-EMT-like cells grow to a larger size than the EMT-like cells. d Quantification of tumor sizes measured as total flux by
in vivo BLI at week 11 (n = 6 injections/group) (asterisk indicates p< 0.005 tested by t-test). Error bars represent SEM. e Representative immunofluorescence
staining of human-specific K19 (red) on mouse lung sections reveals non-EMT-like-derived metastases (n= 4 mice/group). Metastatic colonies stained with
K19 are only found in lungs of mice injected with non-EMT-like cells. Nuclei (blue) and scale bar, 50 μm. f Relative shRNA distributions in Non-EMT-like (left)
and EMT-like (right) MCF7 cells 20 days after transduction with a lentiviral human-specific epigenetic shRNA library (referred as epi-library) in ascending
order. The result is representative of 2 replicates. Negative controls, SCRs, are indicated by green and shFBXO11s in red. shFBXO11s are the most depleted
shRNAs in the non-EMT-like cells compared to the EMT-like cells. g Kaplan-Meier plots of RFS (top) and OS (bottom) of breast cancer patients stratified by
mRNA expression of FBXO11 using a web based survival analysis tool (kmplot.com). A total of 30 cohorts (3951 patients) are split into low (n= 1861) vs.
high (n= 2090) expression groups for RFS (Hazard ratio (HR) = 1.46 (1.31–1.63), log rank p= 2 × 10− 11), and 11 cohorts (1402 patients) are split into low
(n= 468) vs. high (n= 934) expression groups for OS (HR = 1.37 (1.08–1.74), log rank p= 0.01). h FBXO11 stains strongly in highly differentiated breast
carcinomas. Representative immunostaining (brown) of MUC1 (top) or FBXO11 (bottom) out of six highly differentiated luminal breast carcinomas. Biopsy 1
is correctly (left panel) and biopsy 2 is inversely polarized (right panel) based on MUC1 expression and both express FBXO11 in the nuclei. Nuclei (blue)
and scale bar, 50 μm
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MCF7 cells known to differentially express CDH1 and
TWIST, SNAI2, FN and VIM, respectively [3]. Here, using
an RT-qPCR approach different from the one used previ-
ously, the EMT properties of these cells are further sub-
stantiated (Fig. 1a). Also, we confirm the epithelial
properties of the non-EMT-like clone by positive staining
for ZO-1, Occludin and E-cadherin, whereas the
EMT-like clone expresses little of these markers (Fig. 1b).
Notably, transplantation to NOG mice for in vivo imaging
resulted in a significant increase in tumor size of the
non-EMT-like clone compared to the EMT-like (Fig. 1c
and d). Immunofluorescence imaging with keratin 19 fur-
ther revealed that only non-EMT-like cells formed meta-
static colonies in the lungs (Fig. 1e). Since MCF7 breast
cancer cells are considered quite stationary in monolayer
culture [6], we did not pursue migration at the single-cell
level as a readout of EMT. These findings nevertheless
underscore that cancer-cell aggressiveness is not restricted
to cells with a typical EMT-like profile, emphasizing the
need for alternative explanations to this behavior.
Accordingly, we applied a loss-of-function screen
with a lentiviral library of 2365 pLKO shRNA con-
structs (Fig. 1f and Additional files 1 and 2). While
the screen identified several potentially interesting
genes significantly depleted in both clones, here we
focused on differently depleted shRNAs. Among these
were FBXO11, NAT8L and TOX4 in the non-EMT-like
and NAP1L4, TCF20 and ID3 in the EMT-like clones.
Since the non-EMT-like clones are more tumorigenic
and metastatic, we selected FBXO11 for further scru-
tiny (Fig. 1f ).
FBXO11 has been reported to have different cellular
roles. On one hand, it has been shown to keep EMT in
check by facilitating degradation of SNAI1 and SNAI2(reviewed in [7]). On the other hand, FBXO11 has also
been reported to neddylate p53 protein, leading to inhib-
ition of its activity [8]. Since p53 is a bona fide tumor
suppressor, a consequence of FBXO11 expression in this
context would be to promote tumor growth. Accord-
ingly, we show that based on multiple cohorts [9],
FBXO11 is a robust predictor of a poor clinical outcome
in breast cancer (Fig. 1g). To validate the relevance of
FBXO11 specifically in luminal breast cancer which is
the topic of the present study, we examined 30
ER-positive breast cancer biopsies for FBXO11 expres-
sion. We found nuclear staining with FBXO11 in the
majority of the cancer cells in 18 biopsies and six were
highly differentiated, polarized, tubular breast carcin-
omas (Fig. 1h), providing proof of principle that tumors
with FBXO11 expression are not necessarily linked to
EMT. These data were supported by multivariate ana-
lysis of FBXO11 expression and impact on survival, spe-
cifically within the subtype of luminal breast cancer
(Additional file 3: Table S1). Based on these findings,
FBXO11 signaling was further investigated with respect
to tumorigenicity in non-EMT breast cancer cells.
shFBXO11 preferentially attenuates tumor
initiation of non-EMT breast cancer cells
We first tested the knockdown efficiency of shRNAs tar-
geting FBXO11 (shFBXO11s). As expected, in both
clones FBXO11 was reduced by shFBXO11 (Additional
file 3: Figure S1A from which selected lanes were in-
cluded in Fig. 2a, and S1B). Next, we tested the conse-
quences of silencing FBXO11 in terms of tumorigenicity
in vivo. While tumor formation by the non-EMT-like cells
was significantly inhibited by shFBXO11, no effect was
recorded by the EMT-like cells (Fig. 2a and b). Simi-
lar data were obtained with a pGIPZ shFBXO11 (data
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Fig. 2 shFBXO11 preferentially attenuates tumor initiation of non-EMT-like cells. a Non-EMT-like cells (left) and EMT-like cells (right) transduced
with SCR or shFBXO11 and inoculated in NOG mice (103 cells per injection, n = 6 to 10 injections/group). Western blots (first columns of each
panel) illustrate FBXO11 and β-actin expression in inoculated cells. Representative bioluminescent (BL) signal of mice shows a delay in tumor
initiation only in mice inoculated with shFBXO11 non-EMT-like cells. b Relative quantification of tumor growth illustrated in (a). BL signals of each
clone are measured as total flux and normalized by total flux of its corresponding SCR-transduced clone at week 6. Tumor growth is significantly
inhibited only in the FBXO11-depleted non-EMT-like cells (asterisk indicates p < 0.05 tested by ANOVA with Tukey’s test). Error bars represent SEM.
c Sanger sequencing confirming three different FBXO11 indel clones (D7, F4 and G11) as compared to sgRNA target sequence of the CRISPR-
Cas9 gene-editing system. Intact sequence is shown in non-EMT cells and inserted nucleotides are marked in red. F4 clone gained the same indel
mutations in both alleles. d Western blot shows that FBXO11 indel clones do not express FBXO11 proteins. e Tumor volume of non-EMT and
FBXO11 indel clone xenografts as measured in week 6 after injection of 103 cells (n = 6 injections/group, asterisks indicate p < 0.00005 by ANOVA
with Tukey’s test). Error bars represent SD. f Western blot of whole lysates isolated from non-EMT-like- and EMT-like cells transduced with SCR or
shFBXO11 and stained for FBXO11 and p21 shows that p21 is exclusively induced by shFBOX11 in non-EMT-like cells (upper). Western blot of
whole lysates of non-EMT-like cells transduced with either or both of shFBXO11 and shp53 and stained for p53, p21, and β-actin. shFBXO11-
mediated induction of p21 relies on p53 protein (lower). g FBXO11 indel clones significantly induce p21 protein. The percentage of
immunostained p21+ cells in a total of approximately 1000 cells, was automatically counted with image J in triplicates (asterisks indicate p <
0.0005 by ANOVA with Tukey’s test). Error bars represent SD. h Quantification of cell proliferation of GFP+ cells as influenced by shFBXO11 and
shp53 shows that the shFBXO11-induced growth reduction can be partly rescued by shp53 (asterisks ** and * indicate p < 0.0001 and p < 0.005
by t-test, respectively). Error bars represent SD. i Quantification of cell number upon FBXO11 knockout in non-EMT-like cells shows that cell
number in culture is significantly reduced by FBXO11 knockout. Equal numbers (105) of two different FBXO11 indel clones (G11 and F4) or the
control cells (non-EMT-like) were cultured for 8 days prior to cell-counting (asterisk indicates p < 0.01 tested by ANOVA with Tukey’s test). Error
bars, SD. j Quantification of invasive capacity of 5 × 104 control non-EMT-like cells or a FBXO11 indel clone, F4 on Matrigel-coated filters in 72 h.
Note that invasion is significantly abolished by deletion of FBXO11 (asterisk indicates p < 0.05 by t-test). Error bars represent SD of averages of
quadruplicates in two independent experiments. k Depiction of the model used for testing in vitro collective migration (top) and cell invasion
(bottom right). The clusters of mixture of GFP-labeled and unlabeled non-EMT-like cells (1:1 ratio) were either plated in an adhesion culture for
24 h (hrs) (bottom left) or plated in an invasion assay incubated for 72 h (bottom right), followed by staining for K19 (red) and GFP (green). Dual
fluorescence imaging allows for the demonstration of doublets of green/red cells migrating through individual pores by collective migration.
Scale bars, 50 μm
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the non-EMT-like cells, we generated FBXO11 indel
clones, using a CRISPR-Cas9 system (Fig. 2c and d), and
further validated that FBXO11 is necessary for tumorigen-
esis (Fig. 2e). In summary, FBXO11 impacts primarily on
tumorigenicity of non-EMTcells.
Given the known effect of FBXO11 on p53 and the
role of a p53/p21/BCL2 pathway on invasion [7], we
next investigated whether the FBXO11-dependent inhib-
ition of non-EMT-like cells could be explained within
such context. While the clinical datasets were too small
to resolve a potential impact of FBXO11 on e.g. p53
(Additional file 3: Table S1), in culture, shFBXO11 led to
a strong increase in p21 expression in the non-EMT-like
cells but not in the EMT-like cells (Fig. 2f upper, and
Additional file 3: Figure S1C and D). Similar data of p21
induction were obtained with the non-EMT-like cells
deleted for FBXO11 (Fig. 2g). Importantly, the
shFBXO11-induced p21 expression was abolished by
co-transduction with shp53 (Fig. 2f lower). Also func-
tionally, shFBXO11 significantly reduced the cell num-
ber to 37%, which was rescued in part, up to 71%, by
concurrent silencing of p53 (Fig. 2h). These data were
substantiated with two different FBXO11 indel clones
(Fig. 2i). In contrast to the non-EMT cells, the p53/p21
pathway was not appreciably affected by FBXO11 in the
EMT cells. Rather in these cells, FBXO11 led to an
increase in BCL2, which was not pursued further in the
present study (Additional file 3: Figure S1C and D). Insummary, FBXO11 specifically fuels tumor formation in
non-EMT-like cells by restraining the p53/p21 pathway.
In absence of an obvious EMT-based explanation to
tumor aggressiveness, we sought for another mechanism.
The most straightforward candidate process for
EMT-independent invasion and metastasis is that by col-
lective invasion [10]. Here, we decided to gauge for col-
lective cancer-cell invasion in a basement membrane
chamber assay. In an initial experiment we unequivocally
demonstrate that deletion of FBXO11 leads to near
absence of invasion (Fig. 2j). While this was expected,
exactly how the non-EMT-like cells invaded was further
investigated by mixing GFP-labeled and non-labeled
cells in suspension (Fig. 2k). When the clusters were
plated in the invasion assay, cells emerged from single
pores as mixed duplets (Fig. 2k), suggesting that indeed
non-EMT breast cancer cells spread in a collective
manner.
Conclusion
Based on these observations, it is concluded that
FBXO11 is a candidate molecular alternative to the
canonical EMT-dependent aggressiveness in highly
differentiated luminal tumors. In addition, our results
suggest a more prominent role for FBXO11 in
subclone-behavior than hitherto anticipated. This
emphasizes the relevance of considering clonal het-
erogeneity in future therapeutic strategies in breast
cancer.
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